علاج التهاب الإحليل السيلاني الحاد عند الذكور

Authors

  • أيمن حرفوش

Abstract

شملت الدراسة خمسةً وسبعين مريضاً مصاباً بالتهاب الإحليل السيلاني الحاد، والذين راجعوا مشفى الأسد الجامعي في اللاذقية في الفترة الواقعة بين عامي 2007-2005, حيث تم عزل المكورات البنية عند جميع المرضى. قسم المرضى إلى ثلاث مجموعات، تضم كل مجموعة 25 مريضاً حيث أعطيت المجموعة الأولى عقار Pefloxacin 400/mg في اليوم الأول: 800/mg دفعة واحدة مساءً وبعدها400/mg  كل 12ساعة لمدة أربعة أيام حيث حصل المرضى على 4000 /mg. المجموعة الثانية عولجت على الشكل الآتي: تم إعطاء المرضى حقنتين عضليتين بفاصل زمني 48 ساعة من عقار Spectinomycin hydrochloride   2/g. مجموع ما حصل عليه المرضى 4/g. المجموعة الثالثة: عولجت على الشكل الآتي: في البداية تم إعطاء المرضى حقنتين عضليتين بفاصل زمني 48 ساعة من عقار  Spectinomycin hydrochloride   2/g، وبعدها تم إعطاء المرضى عقار Pefloxacin 400/mg بمعدل 400/mg كل 12 ساعة لمدة خمسة أيام حيث حصل المرضى على 4000/mg. إن أفضل النتائج تم الحصول عليها في المجموعة الثالثة حيث حصلنا على الشفاء التام عند جميع المرضى.

The study covered seventy five patients of acute gonococal urethritis. These patients have visited Al Assad University Hospital of Lattakia in 2005-2007. The gonococci were isolated in all patients.

The patients were divided into three groups. Each group consisted of 25 patients. The first group was given Pefloxacin 400/mg. On the first day, they were given 800 mg in the evening and 400 mg every 12 hours for four days. So the patients took 4000 mg. The second group was treated by giving the patients two muscle injections of Spectinomycin hydrochloride 2/g. The period between the two injections was 48 hours. The third group was treated as follows: first, the patients were given two muscle injections of Spectinomycin hydrochloride 2/g. The period between the two injections was 48 hours. Then, the patients were given Pefloxacin 400/mg every 12 hours for five days. So the patients took 4000mg.

The best results were obtained with the third group where all the patients completely recovered.

Downloads

Published

2019-01-16

How to Cite

1.
حرفوش أ. علاج التهاب الإحليل السيلاني الحاد عند الذكور. Tuj-hlth [Internet]. 2019Jan.16 [cited 2024Apr.24];29(3). Available from: https://journal.tishreen.edu.sy/index.php/hlthscnc/article/view/6466

Issue

Vol. 29 No. 3 (2007): العلوم الصحية

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series

 Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series   .  The Readers have the right to send, print and subscribe to the initial version of the article, and the title of  Tishreen University Journal for Research and Scientific Studies - Health Sciences Series  Publisher

journal uses a CC BY-NC-SA license which mean

You are free to:

  • Adapt — remix, transform, and build upon the material
  •  
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

 

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Most read articles by the same author(s)

1 2 > >>